Showing 31 results
- https://www.novartis.com/news/media-releases/novartis-data-underpin-long-term-efficacy-aimovig-where-other-treatments-have-failedData from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
- https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovig-erenumab-prevention-migraineIf approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package…
- https://www.novartis.com/news/media-releases/novartis-data-confirm-long-term-efficacy-and-safety-aimovig-majority-patients-episodic-migraineThe 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig® (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years…
- https://www.novartis.com/news/media-releases/novartis-highlight-extensive-long-term-safety-and-efficacy-data-aimovig-across-spectrum-migraine-aanAfter long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study…
- https://www.novartis.com/news/media-releases/novartis-data-show-aimovig-cuts-acute-migraine-medication-days-half-patients-who-failed-prior-preventive-therapiesData from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures STRIVE…
- https://www.novartis.com/news/media-releases/novartis-announces-lancet-publication-pioneering-study-migraine-prevention-showing-efficacy-aimovig-where-other-treatments-have-failedThe LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported…
- https://www.novartis.com/news/media-releases/novartis-marks-new-era-migraine-patients-eu-approval-aimovig-first-its-kind-treatment-specifically-designed-migraine-preventionPatients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and…
- https://www.novartis.com/news/media-releases/novartis-presents-new-data-demonstrating-long-term-efficacy-safety-and-tolerability-aimovig-erenumab-patients-chronic-and-episodic-migraineResults from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be…
- https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iv-study-showing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-preventionThe first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and…
- https://www.novartis.com/news/media-releases/novartis-announces-new-publication-cephalalgia-data-showcasing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-preventionHER-MES, a Phase IV study, is the first and only randomized, double blind, head-to-head study that compares an antibody targeting the CGRP pathway, Aimovig® (erenumab), with an oral prophylactic…